ConformanceX addresses a proven, widespread and hugely costly need, and offers investors the potential for strong returns.

Here’s yet another example of a drug launch failure:

Case Study

A top ten pharma company was due to launch a new heart drug.

A range of launch teams were assembled, from medical to marketing, and a date was set.

But at the last minute, it was realised a key data point needed for the launch had been missed.

That required the rerunning of the final study, with damaging results for the company:

  • - postponement of launch by one year
  • - a cost estimated at $20 million
  • - and that’s just one example among hundreds, with the number growing every month.

The power of our ability to greatly reduce such damaging losses means:

Within five years we anticipate annual revenues in excess of $30 million.